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Abstract: The Ontario Rabies Vaccine (ONRAB) is a human adenovirus rabies glycoprotein recombi-
nant oral vaccine immunogenic for small Indian mongooses when delivered by direct instillation into
the oral cavity. We offered Ultralite baits containing ~1.8 mL 109.5 TCID50 ONRAB oral rabies vaccine
to 18 mongooses, while 6 mongooses were offered identical baits in placebo form. We collected
sera from individual mongooses at days 0, 14 and 30 post vaccination (pv) and quantified rabies
virus neutralizing antibodies (RVNA) using the rapid fluorescent focus inhibition test, with titers
greater than or equal to 0.1 IU/mL considered positive. All study subjects were RVNA negative prior
to bait offering. Bait consumption was variable: all 6 sham and 13 of 18 (72%) treatment animals
consumed/punctured the baits offered. By day 30 pv, RVNA were detected among 11 of 13 (84.6%)
of treatment mongooses that consumed/punctured baits, whereas sham-vaccinated mongooses re-
mained RVNA negative throughout the study. We conclude ONRAB is immunogenic for mongooses
by Ultralite bait delivery, although the bait design may need further optimization.
Keywords: Urva auropunctata; ONRAB; rabies; small Indian mongoose; Ultralite bait
1. Introduction
The small Indian mongoose (Urva auropunctata; formerly Herpestes auropunctatus) is
a rabies reservoir on Puerto Rico and other Caribbean Islands [1]. In the United States
and Europe, oral rabies vaccination (ORV) is an important tool in managing rabies in wild
carnivores [2,3]. However, no oral rabies vaccine is licensed for use with mongooses. The
product currently licensed for use with raccoons (Procyon lotor) and coyotes (Canis latrans)
in the United States (RABORAL V-RG, Boehringer Ingelheim Animal Health, Athens, GA,
USA) is reportedly not immunogenic for mongooses [4]. However, a vaccine in Europe
(RABITEC; Ceva Santé Animale, Dessau Rosslau, Germany) registered for red foxes (Vulpes
vulpes) and raccoon dogs (Nyctereutes procyonoides) has been reported as immunogenic
for mongooses [5]. The Ontario Rabies Vaccine (ONRAB; Artemis Technologies, Inc.,
Guelph, ON, Canada) is a human adenovirus rabies glycoprotein recombinant oral vaccine
licensed for use with striped skunks (Mephitis mephitis) in Canada, and has been under
experimental use in the United States since 2011 [6–9]. ONRAB was immunogenic for
small Indian mongooses when delivered by direct instillation into the oral cavity [10], but
a bait format for oral delivery has not been attempted. Our objective was to conduct a
preliminary evaluation regarding the immunogenicity of ONRAB delivered to mongooses
via Ultralite baits used to target other wild carnivore reservoirs and vectors of rabies virus
in North America.
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2. Materials and Methods
2.1. Study Area
We conducted this study at the United States Department of Agriculture, Animal
and Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center
Hawaii field station, Hilo, Hawaii, USA. Hawaii is considered free of animal rabies.
2.2. Animal Capture and Husbandry
We live captured mongooses in cage traps (Tomahawk Trap Co., Hazelhurst, WI,
USA) and transported them to the field station where they were housed individually in
60 × 60 × 40 cm3 stainless steel cages. Mongooses were held in acclimation for five to
seven days prior to study initiation. Mongooses were maintained on a daily ration of
~50 g commercial dry cat food, supplemented twice weekly with commercial raw chicken.
Water was available ad libitum. Ambient temperature in the laboratory was maintained at
24–26 ◦C with a 12 h/12 h day/night cycle to mimic mongoose diurnal activity periods.
Humidity in the laboratory ranged from 60 to 90%. Individual mongoose identification
was maintained throughout the study by cage labels containing the cage number and
individual animal microchip number. This study was conducted under Animal Biosafety
Level 2 conditions.
2.3. Bait Description
The Ultralite bait is composed of a 30 × 14 × 10 mm3 elongated oval foil blister pack
with a rectangular lip extending to 40 × 20 mm2 ([6], Figure 1). Previous research found
cheese-flavored Ultralite baits were preferred by mongooses in field trials in comparison to
coconut or fish-flavored baits [11]. Each cheese-flavored bait contained ~1.8 mL 109.5/mL
TCID50 of ONRAB (Bait lot number OTF 18–26, Manufactured 26 March 2018, Artemis
Technologies, Inc., Guelph, ON, Canada). Cheese-flavored control baits contained an
equivalent volume of sterile water.
Figure 1. Ultralite ORV baits coated with external bait matrix.
2.4. Bait Offering
We offered each of the 18 mongooses (9M, 9F) a single ONRAB bait and each of the six
other mongooses (3M, 3F) a single placebo bait for 24 h along with their daily food ration
in a free-choice test. Animals were not fasted prior to bait offering. Baits not punctured
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or chewed after 24 h were considered failed delivery. All baits were removed after 24 h.
During the 24 h of bait offering, we made up to three attempts to replace baits recovered
immediately under the animal’s cage.
2.5. Sample Collection
We anesthetized mongooses prior to vaccination and on days 14 and 30 post vaccina-
tion (pv) via inhalation of isoflurane gas or intramuscular injection of 5 mg/kg Telazol®
(tiletamine/zolazepam; Zoetis, Inc., Kalamazoo, MI, USA) and collected blood samples
as previously described [10]. Serum was separated from whole blood and decanted into
cryovials and stored at −80 ◦C until analysis.
2.6. Sample Analysis
We shipped sera to the Rabies Laboratory at Kansas State University (Manhattan, KS,
USA) where rabies virus neutralizing antibodies (RVNA) were quantified using the rapid
fluorescent focus inhibition test [12]. Titers reported as greater than or equal to 0.1 IU/mL
were considered RVNA positive by comparison to a standard rabies immune globulin
(SRIG; WHO lot 2) positive control.
2.7. Statistical Analysis
Geometric mean (SE) titer values were calculated using Microsoft Excel. Supplemen-
tary figures were generated using the program R [13]. Treatment animals with RVNA titers
<0.1 IU/mL on days 14 and 30 pv were assigned a value of 0.05 IU/mL for the purposes of
geometric mean calculations.
3. Results
All study subjects were RVNA negative prior to bait offering. All (6/6) sham animals
and 13/18 (72%; 95% CI 49–88%; 7M, 6F) treatment animals punctured or chewed the bait
within the 24 h offering period. By day 14 pv 7/18 (39%; 95% CI 20–61%) of treatment,
animals (4M, 3F) were RVNA positive. By day 30 pv, 11/18 (61%; 95% CI 39–80%) of
treatment animals (6M, 5F) were RVNA positive. Two treatment animals (1M, 1F; 15%;
95% CI 3–33%) that chewed/punctured baits remained RVNA negative on days 14 and
30 pv. All sham animals and five treatment animals that did not puncture/consume baits
remained RVNA negative during the study. Geometric mean (SE) RVNA titers among
treatment animals were 0.1 (1.1) and 0.4 (1.3) IU/mL for days 14 and 30 pv, respectively
(Table 1). Individual RVNA serology results are presented in Table 2.
Table 1. Geometric mean (SE) RVNA titer (IU/mL).
Group Day 0 N Day 14 N Day 30 N
Treatment <0.1 18 0.1 (1.1) 7 0.4 (1.3) 11
Sham <0.1 6 <0.1 6 <0.1 6
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Table 2. Individual RVNA titers in 24 small Indian mongooses (Urva auropunctata) prior to treatment and days 14 and 30
post-offering of Ontario Rabies Vaccine Ultralite baits. * Sample collected on day 13.
Animal ID Group Sex
RVNA Titers (IU/mL) Bait Consumed/Punctured
after 24 h? (Y/N)Day 0 Day 14 pv Day 30 pv
25 Sham F <0.1 <0.1 <0.1 Y
8 Sham F <0.1 <0.1 <0.1 Y
27 Sham M <0.1 <0.1 <0.1 Y
28 Sham F <0.1 <0.1 <0.1 Y
29 Sham M <0.1 <0.1 <0.1 Y
30 Sham M <0.1 <0.1 <0.1 Y
13 Treatment M <0.1 <0.1 * <0.1 N
14 Treatment M <0.1 <0.1 <0.1 N
10 Treatment F <0.1 <0.1 <0.1 N
20 Treatment F <0.1 <0.1 <0.1 N
26 Treatment F <0.1 <0.1 <0.1 N
16 Treatment M <0.1 <0.1 <0.1 Y
22 Treatment F <0.1 <0.1 <0.1 Y
3 Treatment M <0.1 <0.1 0.1 Y
5 Treatment M <0.1 0.1 0.1 Y
7 Treatment M <0.1 <0.1 0.2 Y
12 Treatment F <0.1 <0.1 0.3 Y
19 Treatment F <0.1 0.1 0.5 Y
23 Treatment F <0.1 <0.1 0.6 Y
18 Treatment M <0.1 0.1 0.9 Y
1 Treatment M <0.1 0.4 1.1 Y
6 Treatment F <0.1 3.3 1.3 Y
24 Treatment F <0.1 0.8 3.0 Y
11 Treatment M <0.1 1.2 10 Y
4. Discussion
Our research suggests that ONRAB is immunogenic for mongooses when delivered
via the Ultralite bait and 84.6% of treatment animals that consumed/punctured baits
demonstrated induction of RVNA by day 30 pv. However, overall bait consumption sug-
gests further research into bait optimization may be required prior to field evaluation. For
example, of the 18 treatment mongooses in this study, 2 mongooses that punctured/chewed
baits did not demonstrate RVNA seroconversion, suggesting inefficient oral contact with
the vaccine or vaccine spillage from the bait during handling, and 5 treatment animals
did not interact with baits at all. It is notable that day 14 and day 30 pv RVNA titers were
reduced following bait presentation versus DIOC application of ONRAB to individual
mongooses across independent studies with identical vaccine dose and serological methods
(Figure S1 [10]). The fact that overall RVNA titers were lower following vaccine delivery
by bait when contrasted with DIOC delivery was expected [14] lends further evidence to
support the notion that while ONRAB may be immunogenic for mongooses, the bait used
to deliver the vaccine needs refinement. Additional refinement of the bait attractant(s) is
important based on the results of this study, as 20% of the mongooses did not interact with
the baits in this free-choice setting. Modifying the bait structure and shape (e.g., soft and
more cylindrical) to suit the narrow shape of the mongoose mouth could facilitate bait
handling during consumption to reduce potential for vaccine spillage and/or inefficient
oral contact. This study was conducted as a free-choice test with well-fed study subjects,
and bait uptake behavior by free-ranging mongooses in the field may be different based on
the resources available.
In considering the threshold of 0.5 IU/mL established to assess rabies vaccination
in wildlife [15], 3/18 (17%) of mongooses on day 14 pv, and 7/18 (39%) on day 30 pv
demonstrated RVNA equal or greater than 0.5 IU/mL. The range of RVNA values found
in this study (0.1–10 IU/mL, 30 days pv) raises questions of whether mongooses on the
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lower end of the range (i.e., <0.5 IU/mL) would survive post vaccination virus challenge.
Previous research using an experimental vaccine (SPBNGA-S; [4]) suggests that mongooses
on the higher end of this range (≥0.5 IU/mL) may survive a lethal rabies virus challenge
but at the lower end, the degree of protection remains uncertain without further efficacy
evaluation. At this stage in research and development, bait refinement would likely precede
a captive or field efficacy evaluation.
Additional areas of future research may include immunopathology of the tonsils and
oral cavity to evaluate variable vaccine uptake by mongooses in the laboratory [16] as well
as behavioral studies documenting mongoose–bait interaction. Lastly, biomarkers could be
used to provide sensitive and quantitative estimates of bait uptake to aid in optimization
for this species [17]. Limited field trials with a placebo ORV bait targeting mongooses have
been conducted [11,18], but fewer data are available regarding uptake of ONRAB Ultralite
baits by free-ranging mongooses. The control of rabies virus circulation in mongooses
in areas like the Caribbean is an exciting new frontier for adaptation of ORV strategies,
methods and products for this invasive tropical reservoir host.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/v13050734/s1, Figure S1: Geometric mean RVNA titers from mongooses offered ~1.8 mL
109.5/mL TCID50 ONRAB oral rabies vaccine by bait (this study) verses DIOC [10] on day 14 pv,
Figure S2: Geometric mean RVNA titers from mongooses offered ~1.8 mL 109.5/mL TCID50 ONRAB
oral rabies vaccine by bait (this study) verses DIOC [10] on day 30 pv.
Author Contributions: Conceptualization, A.R.B. and A.T.G.; methodology, A.R.B. and A.T.G.;
implementation A.R.B., I.L.L., M.J.R.-R.; formal analysis, A.R.B., and A.T.G.; writing—original draft
preparation, A.R.B. and A.T.G.; writing—review and editing, A.R.B., A.T.G., I.L.L. and M.J.R.-R.;
supervision, A.T.G.; project administration, A.T.G. All authors have read and agreed to the published
version of the manuscript.
Funding: This research was funded by the United States Department of Agriculture, Animal and
Plant Health Inspection Service, Wildlife Services, National Rabies Management Program.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the United States Department of Agriculture, Animal and
Plant Health Inspection Service, Wildlife Services, National Wildlife Research Center’s Institutional
Animal Care and Use Committee under study protocol QA-3005 on 26 March 2019.
Data Availability Statement: The data presented in this study are available in this article and its
Supplemental Material.
Acknowledgments: Thanks to Artemis Technologies, Inc. (Guelph, ON, Canada), for providing baits
and vaccine.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.
References
1. Seetahal, J.F.R.; Vokaty, A.; Vigilato, M.A.N.; Carrington, C.V.F.; Pradel, J.; Louison, B.; Sauers, A.V.; Roopnarine, R.; Arrebato,
J.C.G.; Millien, M.F.; et al. Rabies in the Caribbean: A Situational Analysis and Historic Review. Trop. Med. Infect. Dis. 2018, 3, 89.
[CrossRef] [PubMed]
2. Mueller, T.F.; Schroeder, R.; Wysocki, P.; Mettenleiter, T.C.; Freuling, C.M. Spatio-temporal use of oral rabies vaccines in fox rabies
elimination programmes in Europe. PLoS Negl. Trop. Dis. 2015, 9, e0003953. [CrossRef] [PubMed]
3. Slate, D.; Algeo, T.P.; Nelson, K.M.; Chipman, R.B.; Donovan, D.; Blanton, J.D.; Niezgoda, M.; Rupprecht, C.E. Oral rabies vaccina-
tion in North America: Opportunities, complexities and challenges. PloS Neglect. Trop. Dis. 2009, 3, e549. [CrossRef] [PubMed]
4. Blanton, J.D.; Meadows, A.; Murphy, S.M.; Manangan, J.; Hanlon, C.A.; Faber, M.-L.; Dietzschold, B.; Rupprecht, C.E. Vaccination
of small Asian mongooses (Herpestes javanicus) against rabies. J. Wildl. Dis. 2006, 42, 663–666. [CrossRef] [PubMed]
5. Vos, A.; Kretzschmar, A.; Ortmann, S.; Lojkic, I.; Habla, C.; Müller, T.; Kasier, C.; Hundt, B.; Schuster, P. Oral vaccination of captive
small Indian mongoose (Herpestes auropunctatus) against rabies. J. Wildl. Dis. 2013, 49, 1033–1036. [CrossRef] [PubMed]
Viruses 2021, 13, 734 6 of 6
6. Rosatte, R.C.; Donovan, D.; Davies, J.C.; Allan, M.; Bachmann, P.; Stevenson, B.; Sobey, K.; Brown, L.; Silver, A.; Bennett, K.; et al.
Aerial distribution of ONRAB® baits as a tactic to control rabies in raccoons and striped skunks in Ontario, Canada. J. Wildl. Dis.
2009, 45, 363–374. [CrossRef] [PubMed]
7. Slate, D.; Chipman, R.B.; Algeo, T.P.; Mills, S.A.; Nelson, K.M.; Croson, C.K.; Dubovi, E.J.; VerCauteren, K.; Renshaw, R.W.;
Atwood, T.; et al. Safety and immunogenicity of Ontario rabies vaccine bait (ONRAB) in the first US field trial in raccoons
(Procyon lotor). J. Wildl. Dis. 2014, 50, 582–595. [CrossRef] [PubMed]
8. Gilbert, A.T.; Johnson, S.R.; Nelson, K.M.; Chipman, R.B.; VerCauteren, K.C.; Algeo, T.P.; Rupprecht, C.E.; Slate, D. Field trials of
Ontario rabies vaccine bait in the northeastern USA, 2012–14. J. Wildl. Dis. 2018, 54, 790–801. [CrossRef] [PubMed]
9. Pedersen, K.; Gilbert, A.T.; Nelson, K.M.; Morgan, D.P.; Davis, A.J.; VerCauteren, K.C.; Slate, D.; Chipman, R.B. Raccoon (Procyon
lotor) response to Ontario Rabies Vaccine Baits (ONRAB) in St. Lawrence County, New York, USA. J. Wildl. Dis. 2019, 55, 645–653.
[CrossRef] [PubMed]
10. Berentsen, A.R.; Ellis, C.K.; Johnson, S.R.; Leinbach, I.L.; Sugihara, R.T.; Gilbert, A.T. Immunogenicity of Ontario rabies vaccine
for small Indian mongooses (Herpestes auropunctatus). J. Wildl. Dis. 2020, 56, 224–228. [CrossRef] [PubMed]
11. Berentsen, A.R.; Johnson, S.R.; VerCauteren, K.C. Bait matrix flavor preference by mongoose (Herpestes auropunctatus) in Puerto
Rico: Implications for oral rabies vaccination. Caribb. J. Sci. 2014, 48, 52–58. [CrossRef]
12. Yager, M.L.; Moore, S.M. The rapid fluorescent focus inhibition test. In Current Laboratory Techniques in Rabies Diagnosis, Research
and Prevention; Rupprecht, C., Hagarajan, T., Eds.; Academic Press: San Diego, CA, USA, 2015; Volume 2, pp. 199–215.
13. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2019.
14. Blancou, J.; Schneider, L.G.; Wandeler, A.; Pastoret, P.P. Vaccination du renard roux (Vulpes vulpes) contre la rage par voie orale.
Bilan d’essais en station expérimentale. Rev. Ecol. Terre Vie 1985, 40, 249–255.
15. Moore, S.M.; Gilbert, A.; Vos, A.; Freuling, C.M.; Ellis, C.; Kliemt, J.; Müller, T. Rabies virus antibodies from oral vaccination as a
correlate of protection against lethal infection in wildlife. Trop. Med. Infect. Dis. 2017, 2, 31. [CrossRef] [PubMed]
16. Te Kamp, V.; Freuling, C.M.; Vos, A.; Schuster, P.; Kaiser, C.; Ortmann, S.; Kretzschmar, A.; Nemitz, S.; Eggerbauer, E.; Ulrich,
R.; et al. Responsiveness of various reservoir species to oral rabies vaccination correlates with differences in vaccine uptake of
mucosa associated lymphoid tissues. Sci. Rep. 2020, 10, 2919. [CrossRef] [PubMed]
17. Berentsen, A.R.; Sugihara, R.T.; Payne, C.G.; Leinbach, I.; Volker, S.F.; Vos, A.; Ortmann, S.; Gilbert, A.T. Iophenoxic acid
as a biological marker for oral rabies vaccination in the small Indian mongoose (Herpestes auropunctatus). J. Vis. Exp. 2019.
[CrossRef] [PubMed]
18. Berentsen, A.R.; Chipman, R.B.; Nelson, K.M.; Gruver, K.S.; Boyd, F.; Volker, S.F.; Davis, A.J.; Vos, A.; Ortmann, S.; Gilbert, A.T.
Placebo Oral Rabies Vaccine Bait Uptake by Small Indian Mongooses (Herpestes auropunctatus) in Southwestern Puerto Rico. J.
Wild. Dis. 2020, 56, 452–456. [CrossRef] [PubMed]
